Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR-OIN-17012575Phase 2Recruiting
Phase 2, open-label trial of Rivoceranib, docetaxel, fluorouracil and folinic acid in Esophago-Gastric Adenocarcinoma (2 arms), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: R0 resection rate. Started Dec 2016; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR-OIN-17012575.